Anna M Jankowska

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11539136/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The potential of DNA modifications as biomarkers and therapeutic targets in oncology. Expert Review of Molecular Diagnostics, 2015, 15, 1325-1337.	3.1	26
2	Mutational analysis of RNA splicing machinery components in 206 children with myeloid malignancies. Leukemia Research, 2012, 36, e215-e217.	0.8	1
3	Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis. Blood, 2012, 119, 3203-3210.	1.4	343
4	Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis. Blood, 2012, 119, 6109-6117.	1.4	105
5	Topography, Clinical, and Genomic Correlates of 5q Myeloid Malignancies Revisited. Journal of Clinical Oncology, 2012, 30, 1343-1349.	1.6	95
6	Mutational Determinants of Epigenetic Instablity in Myeloid Malignancies. Seminars in Oncology, 2012, 39, 80-96.	2.2	4
7	Single Nucleotide Polymorphism Array Lesions, TET2, DNMT3A, ASXL1 and CBL Mutations Are Present in Systemic Mastocytosis. PLoS ONE, 2012, 7, e43090.	2.5	97
8	Loss of expression of neutrophil proteinase-3: a factor contributing to thrombotic risk in paroxysmal nocturnal hemoglobinuria. Haematologica, 2011, 96, 954-962.	3.5	12
9	Mutational spectrum analysis of chronic myelomonocytic leukemia includes genes associated with epigenetic regulation: UTX, EZH2, and DNMT3A. Blood, 2011, 118, 3932-3941.	1.4	290
10	CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia. Blood, 2011, 117, e198-e206.	1.4	143
11	Defining the Topography of Deletion 5q Using SNP-A Identifies Patients with More Aggressive Disease and Correlates with Additional Lesions. Blood, 2011, 118, 2795-2795.	1.4	0
12	Acquired Molecular Defects in Spliceosome Machinery: Novel Pathogenetic Pathways in Myeloid Leukemogenesis. Blood, 2011, 118, 271-271.	1.4	9
13	Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Blood, 2010, 115, 1969-1975.	1.4	94
14	Spectrum of mutations in RARS-T patients includes TET2 and ASXL1 mutations. Leukemia Research, 2010, 34, 969-973.	0.8	37
15	Spectrum of molecular defects in juvenile myelomonocytic leukaemia includes <i>ASXL1</i> mutations. British Journal of Haematology, 2010, 150, 83-87.	2.5	64
16	Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature, 2010, 468, 839-843.	27.8	1,160
17	Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms. Blood, 2009, 113, 6403-6410.	1.4	351
18	Involvement of TET2 in Regulation of Epigenetic Silencing in MDS and Related Myeloid Malignancies Blood, 2009, 114, 2908-2908.	1.4	2

#	Article	IF	CITATIONS
19	SNP Arrays Facilitate Genotyping of Non-Synonymous SNP in MDS To Identify Disease Susceptibility Loci Blood, 2007, 110, 2421-2421.	1.4	0
20	Decreased Expression of Membrane-Bound Proteinase 3 by a GPI-Deficient Granulocytes May Contribute to Thrombophilic Propensity in PNH Blood, 2007, 110, 3673-3673.	1.4	3